Use of phosphonocarboxylic acids as inhibitors of sodium-phosphate cotransport

General Pharmacology

Volumn 27, Issue 2, 1996, Pages 305-312

  Loghman Adham, Mahmoud ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

biological transports; brush border membrane; foscarnet; phosphate

Indexed keywords

ANTIVIRUS AGENT; ETIDRONIC ACID; FOSCARNET; HYDROXYAPATITE; PHENYLPHOSPHONIC ACID; PHOSPHATE; PHOSPHONOACETIC ACID; PHOSPHONOPROPIONIC ACID; RADIOISOTOPE; SODIUM; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; BRUSH BORDER; CHRONIC KIDNEY FAILURE; DIET; DRUG ABSORPTION; DRUG BIOAVAILABILITY; HUMAN; INTESTINE; INTESTINE ABSORPTION; INTRAPERITONEAL DRUG ADMINISTRATION; KIDNEY; MEMBRANE TRANSPORT; NONHUMAN; ORAL DRUG ADMINISTRATION; PARENTERAL DRUG ADMINISTRATION; PHOSPHATE METABOLISM; PHOSPHATURIA; PRECIPITATION; PRIORITY JOURNAL; REVIEW;

EID: 0029922429     PISSN: 03063623     EISSN: None     Source Type: Journal    
DOI: 10.1016/0306-3623(95)02017-9     Document Type: Article

References (92)

1. Albert D. A. and Gudas L. J. (1986) Selection and characterization of mutant S49 T-lymphoma cell lines resistant to phosphonoformic acid: evidence for inhibition of ribonucleotide reductase. J. Cell. Physiol. 127, 281-287.
2. Al Mahrouq H. A. and Kempson S. A. (1991) Photoaffinity labeling of brush-border membrane proteins which bind phosphonoformic acid. J. Biol. Chem. 266, 1422-1427.
3. Arar M., Wilson P., Cooper J. and Levi M. (1990) Phosphonoformic acid inhibits rat renal brush border membrane Na-sulfate cotransport activity. J. Am. Soc. Nephrol. 1, 574A.
4. Baxter L. A., DeLuca H. F., Bonjour J-P. and Fleisch H. A. (1974) Inhibition of vitamin D metabolism by ethane-1-hydroxy-1-diphosphonate. Arch. Biochem. Biophys. 164, 655-662.
5. 4 symporter in renal brush border. Am. J. Physiol. 265, F323-F326.
6. +-dependent phosphonoformic acid binding and phosphate transport in renal brush border membrane vesicles. Biochim. Biophys. Acta 1028, 110-116.
7. i cotransporter, in rabbit kidney proximal tubules. II. Localization by immunohistochemistry. Pfluger's Arch. 424, 210-215.
8. Cacoub P., Deray A., Beaumelou A., LeHoang P., Rozenbaum W., Gentilini M., Soubrie C., Roisselle F. and Jacbos C. (1988) Acute renal failure induced by foscarnet: 4 cases. Clin. Nephrol. 29, 315-318.
9. Caverzasio J., Rizzoli R. and Bonjour J-P. (1986) Sodium-dependent phosphate transport inhibited by parathyroid hormone and cyclic AMP stimulation in an opossum kidney cell line. J. Biol. Chem. 261, 3233-3237.
10. Chrisp P. and Clissold S. P. (1991) Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunosuppressed patients with cytomegalovirus retinitis. Drugs 41, 104-129.
11. Crumpacker C. S. (1992) Mechanism of action of foscarnet against viral polymerases. Am. J. Med. 92 (suppl. 2A), 3S-7S.
12. i cotransport in rat kidney: localization by RT-PCR and immunocytochemistry. Am. J. Physiol. 266, F767-F774.
13. Derse D., Bastow K. F. and Cheng Y-C. (1992) Characterization of the DNA polymerase induced by a group of herpes simplex virus type I variants selected for growth in the presence of phophonoformic acid. J. Biol. Chem. 257, 10251-10260.
14. Dousa T. P. and Kempson S. A. (1982) Regulation of renal brush border transport of phosphate. Miner. Electrolyte Metab. 7, 112-113.
15. Eriksson B., Öberg B. and Wahren B. (1982) Pyrophosphate analogues as inhibitors of DNA polymerass of cytomegalovirus, herpes simplex virus and cellular origin. Biochim. Biophys. Acta 696, 115-123.
16. Farmer R. M., Heubel P. H. C. and Popov A. I. (1981) Complexation properties of phosphonocarboxylic acids in aqueous solutions. J. Solution Chem. 10, 523-532.
17. Farthing C. F., Dalgleish A. G., Clark A., McClure M., Chanas A. and Gazzard B. G. (1987) Phosphonoformate (foscarnet): a pilot study in AIDS and AIDS-related complex. AIDS 1, 221-225.
18. Fleisch H., Russell R. G. G., Bisaz S., Muhlbauer R. C. and Williams D. A. (1970) The inhibitory effect of phosphonates on the formation of calcium phosphate crystals in vitro and on aortic and kidney calcification in vivo. Eur. J. Clin. Invest. 1, 12-18.
19. Francis M. D., Mussel R. G. and Fleisch H. (1969) Diphosphonates inhibit the formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science 165, 1264-1266.
20. Frank K. B. and Cheng Y. C. (1986) Inhibition of herpes simplex virus DNA polymerase by purine ribonucleoside monophosphonates. J. Biol. Chem. 261, 15109-15113.
21. Gimenez L., Gordon Walker W., Tew W. and Hermann J. A. (1982) Prevention of phosphate-induced progression of uremia in rats by 3-phosphocitric acid. Kidney Int. 22, 36-41.
22. Hasegawa K., Anraku Y., Kasahara M., Akamatsu Y. and Nishijima M. (1990) Isolation and characterization of Chinese hamster ovary cell mutants defective in glucose transport. Biochim. Biophys. Acta 1051, 221-229.
23. Hedin G., Weiland O., Ljunggren K., Stromberg A., Nordenfelt E., Hansson B. G. and Öberg B. (1987). Treatment of fulminant hepatitis B and fulminant hepatitis B and D coinfection with foscarnet. Prog. Clin. Biol. Res. 234, 309-320.
24. Helgstrand E., Eriksson B., Johansson N. G., Lannero B., Larsson A., Noren J. O., Sjoberg B., Stenberg K., Stening G., Stridh S., Öberg B., Alenius S. and Philipson L. (1978) Trisodium phosphonoformate, a new antiviral compound. Science 201, 819-821.
25. Helgstrand E., Flodh H., Lernestedt J. O., Lundstrom J., and Öberg B. (1980) Trisodium phosphonoformate: Antiviral activities, safety evaluation and preliminary clinical results. In Developments in Antiviral Therapy. (Edited by Collier L. H. and Oxford J.), pp. 63-83. Academic Press, New York.
26. Heubel P. H. C. and Popov A. I. (1979) Acid properties of some phosphonocarboxylic acids. J. Solution Chem. 8, 615-625.
27. i cotransport across renal cortical brush border membrane. Biochem. Biophys. Res. Commun. 153, 1152-1158.
28. i cotransporter in renal cortical brush border membranes. J. Biol. Chem. 266, 11528-11536.
29. +-dependent phosphate transport in cardiac sarcolemnal vesicles. J. Biol. Chem. 264, 3904-3908.
30. Jacobson M. A., Crowe S., Levy J., Aweeka F., Gambertoglio J., McManus N. and Mills J. (1988) Effect of foscarnet therapy on infection with human immunodeficiency virus in patients with AIDS. J. Infect. Dis. 158, 862-865.
31. Jacobson M. A., O'Donnell J. J. and Mills J. (1989) Foscarnet treatment of cytomegalo-virus in patients with acquired immunodeficiency syndrome. Antimicrob. Agents Chemother. 33, 736-741.
32. Jacobson M. A., Gamertoglio J. G., Aweeka F. T., Causey D. M. and Portale A. A. (1991) Foscarnet-induced hypocalcemia and effects of foscarnet on calcium metabolism. J. Clin. Endocrin. Metab. 72, 1130-1135.
33. Kempson S. A. (1988) Novel specific inhibitors of epithelial phosphate transport. NIPS 3, 154-157.
34. Lau K. (1989) Phosphate excess and progressive renal failure: the precipitation-calcification hypothesis. Kidney Int. 36, 918-937.
35. Leinbach S. S., Rena J. M., Lee L. F., Isbell A. F. and Boezi J. (1979) Mechanism of phosphonoacetate inhibition of herpes virus induced DNA polymerase. Biochemistry 15, 426-430.
36. Leitman P. S. (1992) Clinical pharmacology: foscarnet. Am. J. Med. 92(suppl. 2A), 8S-11S.
37. Levi M. (1990) Heterogeneity of phosphate transport by brush border membranes from superficial and juxtamedullary cortex of the rat. Am. J. Physiol. 258, F1616-F1624.
38. Lim K. B., Daraisingham S., Thirumoorthy T., Lee C. T., Ling A. E. and Tan T. (1986) Foscarnet (phosphonoformate sodium) in the treatment of recurrent male genital herpes. Ann. Acad. Med. Singapore 15 617-622.
39. Lock T. J., Odom N. J., Tapson J. S., Freeman R. and McGregor C. G. (1987) Successful treatment with trisodium phosphonoformate for primary cytomegalo-virus infection after heart transplantation. J. Heart Transplant. 6, 120-122.
40. i cotransport in small gut brush border by phosphono-carboxylic acids. Am. J. Physiol. 252, G244-G249.
41. Logham-Adham M., Szczepanska-Konkel M. and Dousa T. P. (1992) Phosphate transport in brush border membranes from uremic rats. Response to phosphonoformic acid. J. Am. Soc. Nephrol. 3, 1253-1259.
42. i cotransport in superficial and juxta-medullary cortex. Biochim. Biophys. Acta 1105, 67-74.
43. i transport in opossum kidney cells. Am. J. Physiol. 263, F301-F310.
44. i transport. Am. J. Physiol. 265, F756-F763.
45. Loghman-Adham M. (1993) Role of phosphate retention in the pregression of renal failure. J. Lab. Clin. Med. 122, 15-25.
46. Loghman-Adham M. and Motock G. T. (1993) Use of phosphonoformic acid in chronic renal failure. Proceedings of 1993 Baxter Extramural Grant Program. Blood Purif. 11, 314-315.
47. Loghman-Adham M., Motock G. T. and Levi M. (1994) Enhanced bioavailability of phosphonoformic acid by dietary phosphorus restriction. Biochem. Pharm. 48, 1455-1458.
48. i cotransporters in renal cortical endosomes. Am. J. Physiol. 269, F93-F102
49. Loghman-Adham M. (1996) Phosphonoformic acid and the progression of renal failure in rats. Renal failure (in press).
50. i cotransport. Proc. Natl. Acad. Sci. USA 90, 979-983.
51. Malmstrom K., Strange G. and Murer H. (1987) Identification of proximal tubular transport functions in the established kidney cell line, OK. Biochim. Biophys. Acta 902, 269-277.
52. Mao J. C. H., Otis E. R., vonEsch A. M., Herrin T. R., Fairgrieve J. S., Shipkowitz N. L. and Duff R. G. (1985) Structure-activity studies on phosphonoacetate. Antimicrob. Agents Chemother. 27, 197-202.
53. McKenna C. E., Khwli L. A., Bapat A., Harutunian V. and Cheng Y-C. (1987) Inhibition of herpesvirus and human DNA polymerases by α-halogenated phosphonoacetates. Biochem. Pharmac. 19, 3103-3106.
54. Mills J., Jacobson M. A., O'Donnell J. J., Cederberg D. and Holland G. N. (1988) Treatment of cytomegalovirus retinitis in patients with AIDS. Rev. Infect. Dis. 10, S522-S531.
55. i transport system in cartilage matrix vesicles. Potential role in the calcification process. J. Biol. Chem. 266, 17791-17797.
56. Murer H., Werner A., Reshkin S., Wuarin F. and Biber J. (1991) Cellular mechanisms in proximal tubular reabsorption of inorganic phosphate. Am. J. Physiol. 260, C885-C899.
57. Nylén P. (1924) Beitrag zur Kenntnis der organischenphosphor-verbindungen. Ber. Deutsch Chem. Ges. 57B, 1023-1038.
58. Öberg B. (1989) Antiviral effects of phosphonoformate (PFA, foscarnet sodium). Pharmac. Ther. 40, 213-285.
59. Onwochei M. O. (1993) Role of sodium/phosphate cotransport in myocardial contractile response to inorganic phosphate. J. Cardiovasc. Pharmac. 22, 632-636.
60. Plante G. E., Dubé J., Bouffard L. and Sirois P. (1991) Sodium-phosphate cotransport and vascular reactivity. Clin. Invest. Med. 14, 545-550.
61. Ringdén O., Lonnqvist B., Paulin T., Ahlmén J., Klintmalm G., Wahren B. and Lernestedt J-O. (1986) Pharmacokinetics, safety and preliminary clinical experiences using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipients. J. Antimicrob. Chemother. 17, 373-387.
62. Ritschel W. A., Grummich K. W. and Hussain S. A. (1985) Pharmacokinetics of PFA (trisodium phosphonoformate) after IV and PO administration to beagle dogs and rabbits. Meth. Find. Exp. Pharmac. 7, 41-48.
63. Sabourn C. L. K., Reno J. M. and Boezi J. A. (1978) Inhibition of eukaryotic DNA polymerases by phosphonocetate and phosphonoformate. Arch. Biochem. Biophys. 187, 96-101.
64. Safrin S., Crumpacker C., Chatis P., Davis R., Hafner R., Rush J., Kessler H. A., Landry B. and Mills J. (1991) A controlled trial comparing foscarnet with vidarabine for acyclovir resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. N. Engl. J. Med. 325, 551-555.
65. Sandstrom E. G., Kaplan J. C., Byington R. E. and Hirsch M. S. (1986) Inhibition of human T-cell lymphotropic virus type III in vitro by phosphonoformate. Lancet i, 480-482.
66. Sandstrom E. Antiviral drugs for AIDS. Drugs 31, 463-466.
67. Sarin P. S., Taguchi Y., Sun D., Thornton A., Gallo R. C. and Öberg B. (1985) Inhibition of HTLV-III/LAV replication by foscarnet. Biochem. Pharmac. 34, 4075-4079.
68. Sjövall J., Karlsson A., Ogenstad S., Sandstrom E. and Saarimaki M. (1988) Pharmacokinetics and absorption of foscarnet after intravenous and oral administration to patients with human immunodeficiency virus. Clin. Pharmac. Ther. 44, 65-73.
69. Sjövall J., Bergdahl S., Movin G., Ogenstad S. and Saarimaki M. (1989) Pharmacokinetics of foscarnet and distribution to cerebrospinal fluid after intravenous infusion in patients with human immunodeficiency virus infection. Antimicrob. Agents Chemother. 33, 1023-1031.
70. Stefanova H. I., East J. M. and Lee A. G. (1991) Covalent and non-covalent inhibitors of the phosphate transporter of sarcoplasmic reticulum. Biochim. Biophys. Acta 1064, 321-328.
71. Stenberg K. and Larsson A. (1978) Reversible effects on cellular metabolism and proliferation by trisodium phosphonoformate. Antimicrob. Agents Chemother. 14, 727-730.
72. Stenberg K., Skog S. and Tribukait B. (1983) Effects of foscarnet on the cell kinetics of Madin-Darby canine kidney cells. Biochim. Biophys. Acta 762, 31-35.
73. Stenberg K., Skog S. and Tribukait B. (1985) Concentration-dependent effects of foscarnet on the cell cycle. Antimicrob. Agents Chemother. 28, 802-806.
74. +-dependent transport of phosphate across renal brush border membrane. J. Biol. Chem. 261, 6375-6383.
75. 14C]phosphonoformic acid with renal cortical brush border membranes. J. Biol. Chem. 262, 8000-8010.
76. i cotransport in renal brush border membrane. Biochem. Pharmac. 38, 4191-4197.
77. i cotransporter by α-bromophosphonoacetic acid. Am. J. Physiol. 258, C583-C588.
78. 14C]phosphonoformic acid binding to renal brush border membranes. Am. J. Physiol. 259, F286-F292.
79. +-sulfate cotransport: stimulation by thyroid hormone. Am. J. Physiol. 261, F420-F426.
80. Tew W. P., Mahle C., Benavides J., Howard J. E. and Lehninger A. L. (1980) Synthesis and characterization of phosphocitric acid, a potent inhibitor of hydroxyapatite crystal growth. Biochemistry 19, 1983-1988.
81. + and pH dependent transport of foscarnet via the phosphate carrier system across intestinal brush border membrane. Biochem. Pharmac. 36, 1019-1022.
82. Vaghefi M. M., McKenna P. A. and Robins R. (1986) Synthesis and antiviral activity of certain nucleoside 5′-phosphonoformate derivatives. J. Med. Chem. 29, 1389-1393.
83. VanScoy M., Loghman-Adham M., Onsgard M., Szczepanska-Konkel M., Homa S., Knox F. G. and Dousa T. P. (1988) Mechanism of phosphaturia elicited by administration of phosphonoformate in vivo. Am. J. Physiol. 255, F984-F994.
84. i analogues as inhibitors of human T-lymphotropic virus type III reverse transcriptase. Antimicrob. Agents Chemother. 29, 867-872.
85. i analogues. J. Virol. 56, 996-1001.
86. Walmsley S. L., Chew E., Read S. E., Vellend H., Salit I., Rachlis A. and Fanning M. M. (1988) Treatment of cytomegalovirus retinitis with trisodium phosphonoformate hexahydrate (foscarnet). J. Infect. Dis. 157, 569-272
87. Warren S. and Williams M. R. (1971) The acid-catalyzed decarboxylation of phosphonoformic acid. J. Chem. Soc. (B), 618-621.
88. Werner A. J., Biber J., Palacin M. and Murer H. (1990) Expression of renal transport systems for inorganic phosphate and sulfate in Xenopus laevis oocytes. J. Biol. Chem. 265, 12331-12336.
89. i cotransport system of kidney cortex. Proc. Natl. Acad. Sci. USA 88, 9608-9612.
90. Williams G. and Sallis J. D. (1979) Structure-activity relationship of inhibitors of hydroxyapatite formation. Biochem. J. 184, 181-184.
91. i cotransport by phosphonoformic acid. Biochem. Biophys. Res. Commun. 139, 679-686.
92. i cotransport across renal brush border membrane. Am. J. Physiol. 256, F852-F861.